Clinical Trial Update: NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating NALIRIFOX as second-line chemotherapy for extrapulmonary high-grade neuroendocrine neoplasms; the study is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: NENS | Phase 2 | Status: RECRUITING